StrideBio: Ginkgo touts gene therapy one-stop shop capabilities following acquisition
Ginkgo acquires StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets and as well as gaining ownership of a preclinical asset.
Read full article »
StrideBio is a North Carolina-based biotechnology firm that develops and commercializes gene therapies for the treatment of CNS and cardiovascular disorders.
Read more